| Q36129903 | Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. |
| Q68715270 | Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experime |
| Q35981853 | Anti-tumour efficacy of mouse spleen cells separated with Dolichos biflorus lectin (DBA) in experimental pulmonary metastasis of B16 melanoma cells |
| Q45275105 | Appearance of neuropeptides in ascitic fluid after peritoneal therapy with interleukin-2 and lymphokine-activated killer cells for intraabdominal malignancy |
| Q45023986 | Asbestos fibres inhibit the in vitro activity of ymphokine-activated killer (LAK) cells from healthy individualsand patients with malignant mesothelioma |
| Q43537382 | Augmentative effect of Nocardia rubra cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction |
| Q67593379 | Combination of interleukin-2 and irradiation in therapy of murine tumors |
| Q36229821 | Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases |
| Q68390239 | Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma |
| Q72873372 | Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors |
| Q41700938 | Effect of culture media on lymphokine-activated killer effector phenotype and lytic capacity |
| Q68780719 | Effect of host age upon interleukin-2-mediated anti-tumor responses in a murine fibrosarcoma model |
| Q71018546 | Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours |
| Q36466665 | Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model |
| Q72667359 | Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2 |
| Q69548004 | Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients |
| Q67790460 | Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens |
| Q36354268 | Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection |
| Q72722734 | In vivo activation of NK cells induces inhibition of lung colonization of H-2 positive and H-2 negative fibrosarcoma tumor clones |
| Q68091272 | In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models |
| Q54241204 | Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking. |
| Q69447291 | Induction of cytotoxicity from fresh splenocytes after in vivo administration of cyclophosphamide. Importance of long-term culture with high-dose recombinant interleukin-2 |
| Q43745881 | Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro |
| Q39232767 | Interleukin-2 in cancer treatment: disappointing or (still) promising? A review |
| Q34306890 | Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer |
| Q68931335 | Interleukin-6 enhances the induction of human lymphokine-activated killer cells |
| Q67996144 | Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour |
| Q54199885 | Persistent augmentation of natural-killer- and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance dose. |
| Q35152386 | Prolonged overall survival in gastric cancer patients after adoptive immunotherapy |
| Q41712984 | Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous p |
| Q69054043 | Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor models |
| Q55234599 | The induction of enhanced antitumor effect against a nonimmunogenic tumor by highly immunogenic variants obtained by mutagen treatment. |
| Q34582987 | Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity |